Character | Response | |
---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
Character | Response | |
---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
Class | Active | Resistant |
---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lagier, J.-C., Armougom, F., Million, M., Hugon, P., Pagnier, I., Robert, C., Bittar, F., Fournous, G., Gimenez, G., Maraninchi, M., Trape, J.-F., Koonin, E. V., La Scola, B., & Raoult, D. (2012). Microbial culturomics: paradigm shift in the human gut microbiome study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(12), 1185–1193.
Lineage | Physiology | General | Growth Tolerances | Hydrol./digest./degr. |
|
|
Health: Unknown
Source: human faeces and clinical sources (blood, wound, cerebrospinal fluid - CCUG)
DNA G+C(%): 50–52
|
Opt. T: 35-37℃
|
|
---|
Monosaccharide O/F | Oligosaccharide O/F | Polysaccharide O/F | Polyol O/F | Other O/F |
|
|
|
|
|
---|
Enzymes: General | Enzymes: Carbohydrate | Enzymes: Protein | Enzymes: Arylamidases | Enzymes: Esters/fats |
|
|
|
|
|
---|
Fuel | Usable Metabolites | Metabolites Released | Special Products | Compounds Produced |
|
---|
Penicillins & Penems (μg/mL) | Cephalosporins (μg/mL) | Aminoglycosides (μg/mL) | Macrolides (μg/mL) | Quinolones (μg/mL) |
amoxicillin: S(2)
|
|
|
azithromycin: Var(MIC50): 2, MIC90: 8, RNG: (0.06-8)
erythromycin: Var(MIC50): 4, MIC90: 8, RNG: (0.25-8)
clarithromycin: Var(MIC50): 4, MIC90: 8, RNG: (0.06-8)
roxithromycin: R(MIC50): 8, MIC90: 16, RNG: (0.25-16)
telithromycin: Var(MIC50): 0.5, MIC90: 4, RNG: (0.06-4)
|
ciprofloxacin: S(MIC50): 0.007, MIC90: 0.007, RNG: (<0.003-0.007)
levofloxacin: S(MIC50): 0.015, MIC90: 0.03, RNG: (0.007-0.03)
ofloxacin: S(MIC50): 0.03, MIC90: 0.06, RNG: (0.015-0.06)
sparfloxacin: S(MIC50): 0.003, MIC90: 0.007, RNG: (<0.03-0.015)
|
---|---|---|---|---|
Tetracyclines (μg/mL) | Vancomycin Class (μg/mL) | Polypep/ketides (μg/mL) | Heterocycles (μg/mL) | Other (μg/mL) |
doxycycline: S(0.5)
|
|
|
|
colistin: Sens
|